CCND2 and glioma: The results demonstrated that, independent of the glioma grade, glioma patients with low levels of cyclinD2 expression exhibited a significantly greater survival time, while the survival time of patients with high levels of cyclinD2 was lower (P<0.05, P<0.05; Fig. 3B and C).